PT values were normal 30 minutes after discontinuing the infusions. As expected. blood loss into the surgical wound was substantial in nine animals receiving therapy initiated before restoring flow in the operated vessel (mean 95 mL, range 45 to 130 mL). By contrast, beginning D-FPRCH2CI therapy in five animals 15 minutes after restoring arterial flow, a time when surgical hemostasis had been achieved, prevented excessive blood loss (mean 1 5 mL, range 10 to 35 mL; P < .01 compared with earlier treatment) without compromising the antithrombotic effects. Continuous intravenous infusion of the synthetic antithrombin DFPRCHzCl(l 00 nmol/kg per minute) for 1 hour, beginning immediately after establishing surgical hemostasis, permanently interrupts endarterectomy thrombosis by irreversibly inactivating thrombin bound to the thrombus and retaining already formed hemostatic plugs to prevent surgical bleeding. 0 1993 by The American Society of Hematology.
gical endarterectomy produces a flow surface composed of medial smooth muscle cells, collagen-rich connective tissue matrix, and tissue factor-rich residual atheromatous material that initiate the generation of thrombin and acute platelet thrombus formation and may contribute to the development of subsequent resten~sis.'-~~~-' ' Thrombo-occlusive complications are generally resistant to conventional antithrombotic therapies consisting of oral aspirin, parenteral heparin, or the c o m b i n a t i~n .~~'~'~~'~ This resistance may be related to:
( 1) the potent thrombogenicity of disrupted atherosclerotic plaques,' ' J~ (2) aspirin's inability to block thrombin-mediated platelet (3) inaccessibility of thrombus-bound thrombin to inactivation by the heparin:antithrombin (AT) ~o m p l e x , '~~'~ or (4) neutralization of heparin locally by platelet factor 4 secreted from platelets recruited into forming thrombi."
Thrombin is important in the recruitment of platelets and the formation of occluding thrombi after mechanical arterial ;njury,'.10.20-22 as evidenced by the capacity of direct ATs, such as hirudin or D-F'PRCHzCl, to interrupt acute highshear, platelet-rich thrombus formation on segments of Dacron vascular graft, collagen-coated tubing, or endarterectomized aorta incorporated into arteriovenous shunts of nonhuman primates.zox2' Unfortunately, antithrombotic doses of the direct, AT 111-independent ATs also inhibit platelet hemostatic Thus, safer strategies are needed to eliminate thrombin-mediated platelet-dependent vascular thrombosis.
INTERRUPTION OF ENDARTERECTOMY THROMBOSIS

1763
To determine the capacity of the synthetic irreversible AT peptide D-FPRCH*Cl to safely inhibit thrombus formation following surgical endarterectomy, we infused D-FPRCH2C1 into baboons for 1 hour beginning either immediately before, or 15 minutes after, restoring flow through the operated artery. The study was designed to test the hypothesis that thrombus formation is permanently abolished by short-term treatment with an irreversible AT and that initiating this therapy after achieving hemostasis obviates excessive surgical bleeding without compromising antithrombotic efficacy.
In these studies the baboon was selected as the experimental animal because of its: (1) primate vascular anatomy, (2) close hemostatic similarity to humans, and ( 3 ) previous experience using hirudin and D-FPRCH2Cl in this s p e~i e s .~* ,~~, *~ Direct surgical endarterectomy of normal carotid arteries was used because of its clinical relevance and because endarterectomy, as opposed to balloon angioplasty of normal arteries, induces reproducible deposition of platelet-rich thrombus that is readily quantified by y-camera imaging of autologous "'Inplatelets in vivo.'
MATERIALS AND METHODS
Animals studied. We studied 28 normal baboons (Papio anubis);
half were assigned to receive treatment and the other half served as controls. The animals weighed 8 to 12 kg, and were dewormed and observed to be disease-free for 3 months before use. All procedures were approved by the Institutional Animal Care and Use Committee and conducted in accordance with Federal guidelines (Guide for the Care and Use of Laboratory Animals, National Institutes of Health, Beth&, MD, NIH Publ. No. 86-23). For surgical procedures animals were administered ketamine hydrochloride (20 mg/kg intramuscularly) for induction, 1% halothane by endotracheal tube for anesthetic maintenance, and buprenorphine (0.01 mg/kg every 8 hours as needed) postoperatively. Routine blood pressure and electrocardiographic monitoring were performed throughout the procedure and immediate postoperative period. We administered ketamine hydrochloride (5 to 20 mg/kg intramuscularly) to achieve short-term immobilization for scintillation-camera imaging at 24 and 48 hours postoperatively and for serial duplex examinations.
Carotid endarterectomy was performed through a midline neck incision using a previously described technique? In brief, the common carotid artery was dissected free of surrounding tissues from the clavicle proximally to the carotid bifurcation distally. The common carotid artery was cross-clamped using atraumatic vascular clamps placed at each end of the exposed vessel three minutes after a bolus injection of heparin sulfate (100 U/kg intravenously [IV]; Elkins-Simm Inc, Cherry Hill, NJ) and divided 1 cm proximal to the distal crossclamp. The proximal arterial segment was then everted over curved forceps. After maximal eversion was obtained, a pair of polypropylene stay sutures (7-0) was placed on either side proximally and a second pair was placed distally in the lumen-exposed segment. The endarterectomy was then performed beginning 1 cm from the divided end of the everted vessel segment and continued for a measured distance of 1 cm. This procedure involved mechanical removal ofthe normal intima and a partial thickness of media using forceps and a surgical microscope (32X magnification; Zeiss operating microscope, Oberkochen, Germany). Following endarterectomy, the vessel was returned to its normal configuration, and an end-to-end anastomosis was performed with 7-0 polypropylene suture and continuous technique under 2.5-fold magnification. The wound was closed in layers.
The treated animals received a continuous IV infusion of D-FPRCH,Cl (Calbiochem, La Jolla, CA) (100 nmol/kg per minute)
Surgical carotid endarterectomy.
for 1 hour, initiated either 5 minutes before or 15 minutes after restoration of flow in the operated carotid
We have previously shown that steady-state circulating levels of D-lTRCH2Cl are achieved by 10 minutes after beginning its continuous infusion in this manScintillation camera images were performed at 30,60, and 90 minutes and at 24 and 48 hours after reestablishing flow in the endarterectomized artery. To localize precisely the endarterectomy site with respect to the gamma camera imaging, a 57Co-radioisotope source (approximately 5 pCi) was sealed in a 1.O-cm length of 0.6 mm4.d.
polyethylene tubing (PE-50; Clay Adams Inc, New York, NY). The 57Co-radioisotope source was affixed to the underlying endarterectomy site by suturing it to the adventitia with 7-0 polypropylene sutures. The endarterectomy region of interest was defined by localizing the lower energy 57C0 1 cm source. Subsequently, the higher energy "'Inplatelet activity was measured in the Same region of interest. Through this colocalization technique the endarterectomy site was positively identified despite the absence of detectable "'In-platelet activity following treatment.' This approach was used to obtain reliable measurements when excessive surgical bleeding might confound measurements, particularly in association with reduced platelet deposition. To measure the attenuation of I ' 'In-platelet radioactivity produced by overlying soft tissue, a "'In standard (approximately 5 p Ci "'Insealed within 0.6 mm i.d. polyethylene tubing) was also placed adjacent to the carotid artery and withdrawn after the initial 5-minute image was obtained (see Blood loss was assessed by estimating the volume of blood aspirated during surgery, present in the surgical sponges, and any clotted blood removed from the wound at the time of imaging at 60 and 90 minutes and at 24 hours.
Autologous baboon platelets were labeled with 1 mCi "'In oxine as previously d e s~r i b e d~~~~-~~ and reinjected at least 1 hour before imaging. Labeling efficiencies averaged 90%. "'In-labeled platelets were functionally normal.30
Gamma camera images of both the operated and contralateral normal carotid arteries were acquired continuously for 90 minutes in 5-minute intervals, and at 24 and 48 hours for 5 minutes each with a GE 400T scintillation camera (General Electric, Milwaukee, WI). The data were stored and analyzed on a Medical Data System A3 Computer (Medasys Inc, Ann Arbor, MI). A medium-energy collimator was placed close to the animal. The precise location of the endarterectomy region of interest was determined by imaging the overlying lower energy 57C0 marker. In control endarterectomized animals approximately 10,000 (range 5,000 to 15,000) cpm were accumulated per field.
The "'In-standard adjacent to the carotid artery was then imaged for 5 minutes. After acquiring the initial image, the '"In-source was withdrawn, and the " 'In-activity of the withdrawn internal standard was then measured. The ratio of the I'lIn-standard before and after removal from the wound provided a direct measure of the attenuation produced by intervening tissues on the '"In-activity at the endarterectomy site.'xz7
Total deposited I ' 'In-platelet activity was determined at the endarterectomy site by placing a region of interest representing 0.5 X 1 .O cm on the coordinates previously identified by the 57C0 standard.
Measurements of '' 'In-activity at the endarterectomy site were corrected for background activity by subtracting the "'In-activity in the contralateral, undissected carotid artery using an identically sized region of interest at the appropriate location, thereby yielding deposited radioactivity only. The "'In-activity at the site of endarterectomy was then corrected for tissue attenuation as described above. Activity of a 5-mL whole blood standard was also determined. The activity of the blood standard was also corrected for the small fraction of circulating nonplatelet radioactivity to give platelet-associated "'Inner.20. 25, 26 Platelet imaging procedures.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From activity per milliliter of whole blood. The total platelet deposition, including both labeled and unlabeled platelets, was calculated by dividing the endarterectomy deposited cpm by circulating platelet cpm (blood standard) and multiplying by the circulating platelet count (platelets per milliliter of whole blood) as measured in the blood standard sample. The results were expressed as platelets deposited per I-cm endarterectomy. Although each endarterectomy site involved an area of approximately 1 cmz (average diameter of carotid arteries in these animals was approximately 3 mm), we presented the results directly without manipulation because the structural and vasomotor variability in the diameter of the carotid arteries was not readily quantifiable in situ at the time of the measurement.
Because circulating 'llIn-platelet activity is cleared continuously through normal physiologic mechanisms, platelet accumulation after the acute 30-to 90-minute time period was expressed as the ratio of the "'In-platelet activity at the endarterectomy site to the "'In-platelet activity in blood. This measurement was independent of the size of the animal, the amount of isotope injected, or the extent to which the isotope may have decayed. Radioactivity values in these calculations refer to platelet activity only, with blood and standard values corrected for the small fraction of nonplatelet ' ' ' I n -a c t i~i t y ?~~~~~~ By standardizing both the region of interest and blood standard, and limiting the comparison with platelet-specific activities, this arbitrary value is a reproducible expression of endarterectomy thrombus that is suitable for comparative purposes.
Duplex ultrasound analysis, combining both high resolution B-mode imaging and Doppler spectral flow analysis, was performed to determine patency of the operated carotid artery noninvasively after the 90-minute gamma camera image, and at 24 and 48 hours postoperatively using an ATZ-MK600 duplex scanner (Advanced Technology Labs, Inc, Seattle, WA). This technique has been shown to be an accurate method for verifying patency and occlusion in manipulated vessels in baboon^.^'
Studies of thrombogenic segments in exteriorized arteriovenous
(AV shunts. To investigate the role of thrombus-bound thrombin in the recruitment of platelets into vascular thrombi, and to determine the effects of inactivating bound thrombin on endarterectomy thrombus formation, we studied segments of endarterectomized homologous aorta incorporated into chronic AV shunt^.^'.'^ Six of the animals underwent surgical placement of AV shunts implanted between the femoral artery and vein according to the procedure described previou~1y.l~~'~ Earlier investigations have established that these Teflon-silicone rubber AV shunts do not produce measurable activation of platelets or coagulation fa~tors.'~,~' Constant blood flow rates were maintained at 150 mL/min in the shunts using an adjustable clamp placed distal to the incorporated vascular segments with monitoring by a Doppler ultrasonic flowmeter (Transonic Systems, Inc, Ithaca, NY) and cuff-type transducer that fitted snugly around the silicone rubber tubing. All experiments were performed in awake animals. Fresh baboon aorta (4 to 5 mm id.) was obtained from other donor animals, flushed with saline, and divided into 4-cm lengths. Branches were ligated and specimens were stored in normal saline. Endarterectomies were performed as described previo~sly.'~ In brief, endarterectomy was performed by inverting the segment over curved forceps and pinning it to a firm working surface. Using sharp dissection under 2.5X optical magnification, the intima and inner media were removed for a distance of 1 cm in the central portion of the vessel. After completion of the endarterectomy, each segment was returned to its normal configuration. Each end of the vessel segment was cannulated using a I-cm length of heat-shrinkable Teflon tubing (Small Parts, Inc, Miami, FL) attached to segments of 3-mm i. 
Duplex ultrasound analysis.
were sealed by careful heating, avoiding direct heat to the tissue. The resultant configuration maintained a stable geometry with a smooth transition from vessel to tubing. For imaging, the entire apparatus was connected to additional lengths of 3-mm Silastic tubing and incorporated into the AV shunt system with 2-cm long tapered Teflon connectors (Small Parts, Inc, Miami, FL).
In animals labeled with autologous " 'In-platelets, six untreated aortic segments without endarterectomy served as negative controls, and six untreated endarterectomized aortic segments (EAS) were used as positive controls. " 'In-platelet labeled animals received a continuous IV infusion of D-FPRCH2C1 (100 nmol/kg per min) for 60 minutes using a syringe pump (Harvard Apparatus, Cambridge, MA) begun 10 min before insertion of the EAS into the AV shunt, and monitored by gamma camera imaging for an additional 3 hours. In four unlabeled shunted animals, D-FPRCH2C1 (100 nmol/kg per minute) was infused IV beginning 10 minutes before placing EAS in the shunt and continued for 1 hour. The EAS were then transferred to the shunts of untreated I ' 'In-platelet-labeled animals; platelet deposition was determined throughout the subsequent 3 hours.
For measurements of thrombin activity b u n d to thrombus formed on thrombogenic segments interposed in the AV shunts, segments of Dacron vascular graft were used according to the same protocol as that for EAS, as reported p r e v i o u~l y .~~~~~~~~
In additional unlabeled animals, four replicate graft segments were incorporated into the shunts in series; duplicate EAS were removed after 15 minutes and 60 minutes for measurements of bound thrombin catalytic activity (see below).
Platelet counts, red blood cell (RBC) counts, and white blood cell (WBC) counts were determined before and daily throughout each imaging study using whole blood collected in Na2EDTA (2 mg/mL) and a Baker model 8 10 whole blood analyzer (J.T. Baker, Allentown, PA).9,20.2' The mean platelet count was 318 k 70 X I03/jtL in the control group and 296 2 53 X 103/jtL in the treated group. Bleeding time measurements were performed in duplicate on the shaved volar surface of the forearm, using the standard template method as previously described for studies in baboon^?^*^^^'.^^ Plasma fibrinogen concentrations were measured as thrombin-clottable protein using the method described previously.'9-21 Standard methods were used to determine the activated partial thromboplastin time (APTT) and prothrombin time (PT).'932' Routine blood chemistry determinations were performed preoperatively and postoperatively, including hepatic, cardiac, and renal profiles.
AT activity levels of D-FPRCH2C1 were measured in plasma prepared from blood collected in acid-citrate dextrose (ACD; NIH formula A) obtained before infusion and at 30 and 60 minutes after the start of infusion, and 30 minutes after the cessation of therapy. Plasma antithrombin activity levels were assayed in fresh or flash frozen samples stored at -70°C for subsequent assay, using a standard curve for D-FPRCH2C1 prepared in the animals' own control pretreatment plasma.20*21
Thrombin catalytic activity bound to thrombi formed on thrombogenic segments in AV shunts was measured using thrombin chromogenic substrate determinations (Spectrozyme TH; American Diagnostica, Greenwich, CT), adapted from the report by Hatton et Segments of Dacron vascular graft, prepared as described prev i o u~l y ,~~~~~ were incorporated into chronic exteriorized femoral AV shunts as described a b o~e .~~,~~ After variable periods of exposure to flowing blood and after different treatment periods, the segments were removed and perfused with cold buffer (calcium-and magnesium-free phosphate-buffered saline) at 20 mL/min for 5 minutes. A40rphohg.v. Forty-eight hours after carotid endarterectomy, four control and four treated animals were killed by perfusion fixation with 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer." In brief, after the animals received ketamine analepsis and halothane endotracheal anesthesia, both internal and jugular veins were cannulated for subsequent exit drainage. Mechanical ventilation was initiated and a median sternotomy performed. The pericardium was incised and a 10-gauge needle (connected to perfusion delivery tubing) was inserted into the left ventricle after clamping the aorta distal to the origin of the left common carotid artery. To maintain normal distention of the carotid vessels during fixation, we adjusted the fixative flow in the perfusion system to achieve 90 to 100 torr intra-arterial pressure. Perfusion fixation continued for 30 minutes.
The carotid arteries were resected en-bloc, the attached 57C0 standards were removed, and the specimens were prepared for scanning electron microscopy as described previously!." We used a Hitachi-S 520 electron microscope (Hitachi Scient& Instruments, Mountain View, CA), which was operated at an accelerating voltage of 20 keV.
D&u annlysis Data were analyzed using the CLINFO Plus computer program provided through the Division of Research Resources, National Heart, Lung and Blood Institute, NIH. Comparisons between two groups were performed using the two-tailed Student's ttest, unless the data were not distributed randomly, in which case nonparametric analysis was performed. Analysis of variance was used to compare values for a particular group at various time points. 35 Unless othenvise stated, variance about the mean is given as f 1 SD.
RESULTS
Platelets accumulated rapidly at carotid endarterectomy sites in 14 heparin control studies, reaching a plateau value of 11.7 & 1.61 X lo8 platelets/cm within 90 minutes after reestablishing arterial flow (Fig 1 and Fig 2) . Thereafter, the endarterectomy to blood ratio (EBR) remained elevated throughout the subsequent 48 hours (3.03 k 0.5 1 at 24 hours and 3.25 & 0.48 at 48 hours; P = .759 comparing 24-hour with 48-hour values; Fig 1) . Platelet deposition was similar in rate and pattern on EAS in AV shunts (Fig 3; Table 1 ). The corresponding thrombin catalytic activity bound to thrombus on thrombogenic segments in AV shunts was 2.6 +-0.6 ng/cm 15 minutes after exposure to flowing blood and 1.9 f 0.4 ng/cm after 60 minutes, respectively (Table 1) .
I
By contrast, platelet deposition at endarterectomy sites was reduced to 1.5 1 k 0.40 X lo8 platelet/cm at 90 minutes postoperatively in 14 animals treated with IV D-FPRCH2CI for 1 hour and remained markedly decreased for at least 48 hours (Fig 1 and Fig 2) . Initiating D-FPRCH2CI 5 minutes before reestablishing arterial flow in nine of the treated animals resulted in the deposition of 1.59 +-0.36 X lo8 platelets at 90 minutes ( P < .002, compared with heparin-treated controls).
Therapy with D-FPRCH2C1 begun 15 minutes after restoring flow in five animals reduced platelet deposition to an equivalent extent (1.35 t 0.51; P < ,002 v controls and P > .5 compared with the results of therapy initiated before restoring arterial flow). Similarly, the intravenous D-FPRCH2C1 treatment for 60 minutes in animals bearing EAS in exteriorized shunts eliminated the accumulation of thrombus and abolished thrombin activity at the endarterectomy sites (Table  1) . Continued evaluation for 60 and 180 minutes after discontinuing the 60 minutes IV treatment for 3 hours failed to show significant accumulation of either thrombus or of bound thrombin (Table 1) . When 60 minute-treated EAS were incorporated into the exteriorized shunts of l'In-platelet labeled, but untreated, recipient animals for 60 minutes, neither thrombus nor thrombin accumulated significantly (Fig  3) . Local incubation of endarterectomy thrombus with DFPRCH2Cl, 10 nmol/mL, for 1 O minutes in vitro completely inactivated the thrombin bound to endarterectomy thrombi formed after 15 minutes and 60 minutes of exposure to flowing blood ( P < . O 1 in both cases, compared with corresponding untreated controls; Table 1 ).
The reduction in platelet deposition by infused DFPRCH2Cl was also evident from the initial EBR (0.82 5 0.25 and 0.41 -t 0.25 v 3.03 k 0.5 1 in the two treated groups v controls respectively) 90 minutes after operation ( P c .005 in both cases). This interruption of I ' 'In-platelet deposition on endarterectomized vessels in both treatment groups was sustained throughout the subsequent 48 hours (Fig 1) . EBR at 48 hours was 0.85 k 0.23 and 0.54 k 0.41 in the two D-FPRCH,Cl-treated groups, compared with 3.25 f 0.48 in controls (P > 0.5 for initial v final EBR in the treated and untreated groups; P < .002 for each of the two treated v untreated control final EBR).
Scanning electron microscopy of the treated endarterectomized vascular surfaces 48 hours after endarterectomy demonstrated marked reduction in deposited thrombus in Table 1 
the treated versus control specimens (Fig 4) . All operated vessels were patent in treated animals at 24 hours when assessed by Doppler duplex scanning. Occlusion occurred in 3 of 14 heparin control animals and in none of the treated animals.
Plasma levels of D-FPRCH2CI in the 14 treated animals
were not detectable before infusion, reached 7.2 k 0.9 I pmol/ L at 30 minutes of infusion, 7. I ? 0.87 pmol/L at the conclusion of the infusion period (P > 3, 2.1 ? 0.47 pmol/L 30 minutes later (P < .01, compared with treatment levels) and undetectable the next day. The T5o clearance of D-FPRCH2CI after discontinuing the 1 hour IV administration was 17 minutes. The infusions of D-FPRCH2CI produced no detectable changes in behavior or physiologic performance. Specifically, there were no changes in blood pressure, cardiac rate, electrocardiographic patterns, or routine blood chemistries (including hepatic, cardiac, and renal profiles). Administration of D-FPRCH2CI increased template bleeding times to >30 minutes in all animals during the 1-hour infusion compared with 5.6 k 0.8 minutes before treatment (P < However, the bleeding times were normal by 30 minutes after discontinuing the infusion of DFPRCH2Cl (6.2 k I .3 minutes; P > .5 compared with baseline values). Corresponding increases in the APTTs and PTs were noted during the period oftreatment ( Table 2) . Platelet counts and fibrinogen levels remained unchanged in the blood of treated animals over the course of the study (296 k 53 X lo3 platelets/pL during treatment and 273 & 36 X IO3 platelets/ pL 30 minutes after treatment, P = .73; fibrinogen concentrations were 3.54 k 0.22 mg/mL pretreatment and 3.39 ? 0.31 after treatment, P = .7 1).
In animals receiving D-FPRCH2CI initiated 5 minutes before restoring flow in the operated vessels, the long bleeding times were associated with excessive bleeding into the surgical wound that persisted for several hours; blood loss averaged 95 mL (range 45 to 130 mL: P < .O 1 compared with controls).
Indeed, accumulated blood was generally visible in the wound at 60 minutes, 90 minutes, and at 24 hours after DFPRCH2Cl treatment when therapy was initiated before restoring flow in the operated vessel. In contrast, when D-FPRCH2CI was administered beginning 15 minutes after reestablishing arterial flow, a time when primary surgical hemostasis was uniformly achieved, bleeding in the surgical site was minimal. averaging 15 mL (range 10 to 35 mL). The mean blood loss in heparin controls was less than IO mL.
DISCUSSION
These data show that I-hour IV infusions of the synthetic direct AT peptide D-FPRCH2CI produce lasting interruption of platelet deposition at sites of surgical carotid endarterectomy by irreversibly inactivating thrombin generated by, and bound to, forming thrombus. Moreover, delaying D-FPRCH2CI infusions until surgical hemostasis becomes established obviates the bleeding complications caused by earlier initiation of therapy without compromising the antithrombotic benefits.
Mechanical vascular damage generates thrombin by initiating both tissue factor-dependent and intrinsic activation of factor X (FXa), which together with the cofactor activated factor V (FVa), a phospholipid surface and in the presence of ionic calcium, form the prothrombinase complex that cleaves pr~thrombin.~~." Platelets accumulating at the site of injury actively promote the assembly of the requisite proteolytic complexes that amplify prothrombin's catalytic conversion to Thrombin, in turn, activates ambient platelets, inducing their local recruitment into vascular thrombus.1°.20'22 Thrombin also stabilizes the thrombus by converting entrapped fibrinogen to fibrin.'0*38 Thrombin po- Thrombin also initiates protective mechanisms that limit thrombus extension beyond the site of vascular damage," including the enhanced endothelial production and release of prostacyclin,"' nitric o~i d e , "~ tissue plasminogen activator," and activated protein C.45 D-FPRCH2CI is unique among the plasma AT 111-independent, direct antithrombins because it potently and covalently inactivates thrombin,20-25,46s47 both soluble and thrombus-bound (Table 1) . Recent crystallographic studies clarify the tight three-dimensional fit of this molecule for thrombin's catalytic pocket and its subsequent covalent linkage with His-57 of the active center complex.48 Hirudin, on the other hand, achieves potent and specific AT activity through reversible tight binding with thrombin's exosite without specific interactions directly involving the active enter.^'.^^ Conversely, recently developed boroarginyl derivatives potently block the serine active center without covalent linkage. 50 Previously it has been shown that plateletrich, aspirin-and heparin-resistant thrombi on Dacron vascular grafts,2o vascular stents,26 and hemodialyzersZ5 are interrupted by systemic infusions of D-FPRCH2CI. The dose used in the present study was determined on the basis of results using highly thrombogenic segments of Dacron vascular graft to initiate thrombus formation,20 in which 100 nmol/kg per minute of D-FPRCH2Cl was required to eliminate the formation of thrombus. Although comparable doseresponse data are not presently available for D-FPRCH2CI treatment of endarterectomized arteries, the results using a reversible bifunctional antithrombin peptide, ie, Hirulog, indicate that thrombus forming at sites of endarterectomy may be more responsive to interruption by direct antithrombins than thrombus induced by segments of vascular graft.51 The long-term toxicities associated with systemically administered D-FPRCH2CI have yet to be adequately investigated with respect to its potential as a systemic therapeutic agent in humans.
We postulate that the lasting antithrombotic benefits following brief systemic treatment with DFPRCHzCl are caused by the permanent inactivation of thrombin bound to, and saturating, any already formed thrombus, and possibly other bound serine proteases of the coagulation sequence. This hypothesis presumes that irreversibly inactivated thrombin occupies the binding sites in residual thrombus for many hours, precluding binding of subsequently formed active thrombin and blocking the resultant local catalytic activation of platelets and fibrinogen. As predicted by the present studies, D-FPRCH2CI, but not competitive ATs such as hirudin, interrupt subsequent thrombus formation after topical application at a site of established t h r o m b~s .~' ,~~ More complicated mechanisms of subsequent attenuating thrombogenicity at sites of vascular injury may include carpeting by spent unresponsive platelets, enzyme degradation of medial constituents, or modulation of thrombogenic properties of migrating and proliferating medial cells.
Interestingly, platelet hemostatic plugs are maintained after the 1-hour infusion of D-FPRCH2CI. Retention of surgical hemostasis may reflect impaired endogenous fibrinolysis caused by D-FPRCH2CI inactivation of both tissue plasminogen activator and plasmin in the hemostatic plugs, because they are irreversibly inactivated by the doses used in this study (Cata not shown). Thus, delaying the initiation of D-FPRC. 12CI therapy until surgical hemostasis has been completed prevents abnormal surgical blood loss by retaining hemostatic plugs, without compromising the capacity of D-FPRCH2CI to inactivate thrombin bound to endarterectomy thrombus.
Endarterectomy is a commonly performed, clinical procedure for vascular reconstruction in patients with symptomatic vascular occlusive disease of various organ sysWhile acute thrombotic occlusion is not a frequent complication of carotid endarterectomy procedures, subsequent restenosis develops in about one fourth of the endarterectomized patients during the following year and thrombo-occlusive events occurs in some of these patient^.".'^ Although previous reports using experimental animal models of endarterectomy in nonhuman primates suggests that aspirin improves patency and decreases resten~sis,~~ no benefits have been reported in clinical trials evaluating aspirin-containing regimens. I2.I3 Because endarterectomized normal baboon arteries appear to generate thrombin similar to mechanical damage of tissue factor-rich atherosclerotic human arteries (Table l),3.9."%24 the present findings may be relevant to the thrombotic complications associated with interventional therapies currently used in the management of symptomatic arterial disease in humans, including endarterectomy, angioplasty, endovascular stent placement, and small caliber vascular graft implantati~n.~,~~.''.~~.~~, ~~ It is of interest to compare the antithrombotic effects of D-FPRCH'CI with the alternative strategy for interrupting platelet-rich thrombus formation using agents that inhibit platelet glycoprotein (GP) IIb/IIIa-dependent platelet re~ruitment.'~ Administration of the murine antibodies in baboons34 and humans56 produces dose-dependent antithrombotic effects. However, there are immunogenic consequences, prolonged hemostatic risks, and as yet to be understood thrombocytopenia that complicate their administration. Moreover, no antithrombotic effects were observed in vivo when anti-GPIIb/IIIa antibodies were given in association with the implantation of small caliber femoral artery vascular grafts in baboon^.^' Currently, the relative safety and efficacy of recently developed potent anti-GPIIb/ IIIa peptides are being defined.23. [58] [59] [60] We conclude that acute thrombus formation at sites of vascular injury is a platelet-dependent, thrombin-mediated, and heparin-resistant process that is permanently interrupted by early, transient infusion of the synthetic irreversible antithrombin D-FPRCH2CI. Moreover, in contrast to the excessive surgical bleeding observed when the infusion is begun before restoring arterial flow in the operated artery, initiating terns. 
